In the meta-analysis conducted by Moon et al., 8.3% of patients exhibited concurrent BRAFV600E and TERT promoter mutations, which showed an association with advanced stage, extrathyroidal extension, lymph node metastasis, distant metastasis, increased risk of recurrence and worse survival [9]. Here, TERT is linked to metastatic malignant neoplasm in the lymph nodes.